



(11)

EP 2 775 836 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61P 19/06 ^(2006.01)

(86) International application number:
PCT/US2011/059433

(48) Corrigendum issued on:
24.10.2018 Bulletin 2018/43

(87) International publication number:
WO 2013/066353 (10.05.2013 Gazette 2013/19)

(45) Date of publication and mention
of the grant of the patent:
12.09.2018 Bulletin 2018/37

(21) Application number: **11875217.9**

(22) Date of filing: **04.11.2011**

(54) **METHODS FOR TREATING GOUT FLARES**

VERFAHREN ZUR BEHANDLUNG VON GICHTFÄRBUNGEN

MÉTHODES PERMETTANT DE TRAITER LES ÉRYTHÈMES DE LA GOUTTE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(74) Representative: **Wills, Andrew Jonathan et al**
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(43) Date of publication of application:
17.09.2014 Bulletin 2014/38

(56) References cited:
US-A1- 2011 268 801 US-B1- 6 613 802

(73) Proprietors:
• **CymaBay Therapeutics, Inc.**
Newark, CA 94560 (US)
• **DiaTex, Inc.**
San Antonio, TX 78248 (US)

• **BLUHM G B ET AL: "A double blind study comparing halofenate with probenecid in gout", ARTHRITIS & RHEUMATISM, WILEY, US, vol. 18, no. 4, 1 January 1975 (1975-01-01), pages 388-389, XP009183634, ISSN: 0004-3591**
• **ANONYMOUS: "METABOLEX INITIATES PHASE 2 TRIAL OF ARHALOFENATE Potential Best-in-Class Uricosuric Agent for the Treatment of Gout", INTERNET CITATION, 19 May 2011 (2011-05-19), pages 1-2, XP002682224, Retrieved from the Internet: URL: <http://www.metabolex.com/news/may192011.html> [retrieved on 2012-02-11]**

(72) Inventors:
• **LAVAN, Brian Edward**
NEWARK
CA 94560 (US)
• **SAHA, Gopal Chandra**
NEWARK
CA 94560 (US)
• **ROBERTS, Brian K.**
NEWARK
CA 94560 (US)
• **MCWHERTER, Charles A.**
NEWARK
CA 94560 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 775 836 B8

- Schlesinger N: "Management of acute and chronic gouty arthritis: present state-of-the-art. - PubMed - NCBI", , 1 January 2004 (2004-01-01), XP055181670, Retrieved from the Internet: URL:<http://www.ncbi.nlm.nih.gov/pubmed/15481999> [retrieved on 2015-04-08]